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Background. Neonatal chylothorax is a rare condition, but has a high mortality. Study Objectives. To analyse the outcomes of a
series of neonates with chylothorax and review the literature to determine best practice. Design. A case series review and a
literature review using electronic databases including the key words neonates and chylothorax. Results. Six cases of neonatal
chylothorax were identiﬁed during a ten-year period, two had congenital chylothoraces and four iatrogenic chylothoraces after
thoracic surgery or chest instrumentation. *e neonates were ventilated for a median of 30 (range 13–125) days with a median
maximum daily pleural ﬂuid output of 218 (range 86–310) ml/kg/day. All the neonates were given medium-chain triglyceride
(MCT) feeds which stabilised pleural ﬂuid output in four and reduced it in another. Octreotide was used in three neonates, but the
dosage used had no signiﬁcant eﬀect on pleural output. Two neonates required surgical intervention. *e literature review
demonstrated MCT feeds can reduce or stabilise pleural ﬂuid output, but highlighted variable use of octreotide and inconsistent
dosing regimens and outcomes. No consensus regarding indications for surgical intervention was identiﬁed. Summary and
Conclusion. Neonatal chylothorax is uncommon, but aﬀected neonates require high healthcare utilisation.
1. Introduction
Neonatal chylothorax is a rare condition with an incidence
of 1 in 5775 [1] to 24000 [2] and has a high mortality rate of
up to 64% [2]. Neonatal chylothorax can be congenital or
acquired, the latter most commonly occurs after damage to
the thoracic duct during surgery [3]. We have reviewed our
experience in a tertiary neonatal surgical unit and set this in
the context of a literature review to establish if it was possible
to determine best practice.
2. Case Series
2.1. Method. A retrospective study was undertaken to de-
termine the outcomes of all neonates with neonatal
chylothoraces admitted to a tertiary medical and surgical
neonatal intensive care unit in London, UK, from July 2008 to
July 2018. Neonates were identiﬁed through the hospital
clinical coding and an electronic database (BadgerNet). *e
diagnosis of a neonatal chylothorax was made if the pleural
ﬂuid had a cell count of >1000/ml with a lymphocyte pre-
dominance and if the triglyceride level was greater than
1.1mmol/L in a neonate who was being fed [4]. Initial
treatment for our cohort included stabilisation, ventilatory
support, and replacement of pleural ﬂuid losses. Speciﬁc
treatment included medium-chain triglyceride (MCT) feeds,
and then octreotide if the pleural ﬂuid output continued,
followed by surgical intervention if those interventions failed.
A literature review was undertaken using electronic da-
tabases including the key words neonates and chylothorax.
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2.2. Results. *ere were 54,488 births in the study period,
and six neonates were diagnosed with chylothorax, giving a
local overall incidence of 1 in 9081 births. *e six neonates
had a median gestation of 37 + 6 (range 33 + 5 to 39 + 6)
weeks and a median birth weight of 2935 (range 2252–4078)
grams (Table 1). All neonates had a “lymphocytic” eﬀusion,
and three had a raised pleural ﬂuid triglyceride of 2.2 (range
1.7–3.2) mmol/L. Two neonates had genetic variants of
unknown signiﬁcance and one, with subtle dysmorphic
features, had a benign copy variant of paternal inheritance.
Four neonates required intubation in the delivery suite,
and all required an extended period of mechanical venti-
lation with a median duration of 30 (range 13–125) days
(Table 1). Two neonates required high-frequency oscillation
ventilation and inhaled nitric oxide. Five neonates were
successfully extubated and self-ventilating in air by a median
of 37 (range 30–78) days. *e neonates required a median of
ﬁve (range 2–6) chest drains for a median duration of 36
(range 28–99) days. *e median maximum total daily
pleural ﬂuid output was 218 (range 86–310) ml/kg/day. *e
majority of pleural drain losses were replaced by human
albumin solution (HAS) or occasionally by 0.9% saline or
fresh frozen plasma (FFP).
All the neonates required total parental nutrition and
were commenced on MCT feeds after diagnosis. Five
achieved full MCT feeds at a median of 37 (range 11–44)
days of age. One neonate had resolution of the chylothorax
following introduction ofMCTfeeds. In four neonates, MCT
feeds were associated with stabilisation of the pleural ﬂuid
output. Two neonates were graded back to either a standard
neonatal formula or maternal expressed breast milk, and
three were discharged on MCT feeds. One neonate had
increased pleural ﬂuid output after the introduction of MCT
feeds which were subsequently stopped and the neonate
remained on total parental nutrition until reorientation of
care.
*ree neonates were treated with a continuous octreo-
tide intravenous infusion for a median of seven (range 6–16)
days with a starting dose of 1-2micrograms/kg/hr to a
maximum of 2–8micrograms/kg/hr. One neonate de-
veloped transient hypothyroidism and, therefore, remained
on low-dose octreotide at 2micrograms/kg/hr, which was
stopped after thoracic duct ligation. Octreotide was stopped
in the other two neonates as there was no reduction in
pleural ﬂuid output. Two neonates with acquired chylo-
thorax required operative intervention. One had a successful
thoracic duct ligation and one had bilateral pleurodesis, but
this failed to improve the neonate’s outcome. Five neonates
survived, and the total length of stay until discharge or death
was a median of 68 (range 44–127) days.
3. Discussion
Neonatal congenital chylothorax is a rare condition as
evidenced by an incidence of 1 in 27,244 in our cohort,
which is in keeping with another study (1 in 24,000 [2]). Our
mortality (17%) is in accordance with other studies [1, 2, 12].
Up to 50% of neonates with neonatal chylothorax can be
associated with genetic syndromes [1, 14]. In our cohort,
although two neonates had genetic variants, none were
found to have a deﬁned syndrome.
In our cohort, only one neonate had a reduction in
pleural ﬂuid output following the introduction of MCT
feeds, but in others the output was stabilised. MCT feeds
Table 1: Perinatal and neonatal characteristics, management, and outcomes.
Neonate
Birth
weight
(g)
Gestation
(weeks) Antenatal
Mode
of
delivery
Resuscitation Diagnoses MCTfeeds
Octreotide
and dose
Ventilation
(days) Outcome
1 3080 39 Normal VD
*ick
meconium
intubated at
10minutes
Acquired NC,
MAS, multiple
pneumothoraces
Yes No 38 Alive
2 2252 33
Hydrops,
bilateral
eﬀusions,
antenatal shunts
VD
Pleural
shunts
clamped &
intubated at
birth
Congenital NC Yes
Yes
(2–8mcg/
kg/hr)
31 Alive
3 4078 38
Left pleural
eﬀusion &
mediastinal shift
CS Intubated atbirth Congenital NC Yes No 28 Alive
4 2790 37 Left CDH VD Intubated atbirth
Acquired NC,
CDH Yes
Yes∗∗
(1–4mcg/
kg/hr)
125 Died
5 2690 38 Polyhydramnios VD Noresuscitation
Acquired NC,
OA, TOF Yes
Yes∗∗
(1–2mcg/
kg/hr)
13 Alive
6 3350 37 Polyhydramnios VD Noresuscitation
Acquired NC,
OA, TOF Yes
∗ No 19 Alive
CDH: congenital diaphragmatic hernia; CS: caesarian section; MAS: meconium aspiration syndrome; MCT: medium-chain triglycerides; NC: neonatal
chylothorax; OA: oesophageal atresia; TOF tracheoesophageal ﬁstula; VD: vaginal delivery; ∗neonate had a reduction in pleural output following introduction
of MCT feeds; ∗∗octreotide was given prior to surgical intervention.
2 Case Reports in Pediatrics
have been shown to be eﬀective in reducing lymphatic ﬂow
in 25% of neonates with surgically related neonatal chylo-
thorax [15]. Indeed, our literature review (Table 2) dem-
onstrated that the majority of neonates who have a neonatal
chylothorax receive MCT feeds.
A systematic review in which the eﬃcacy of octreotide, a
somatostatin analogue, was assessed did not recommend its
use [4]. Our literature review demonstrated since then
multiple case series in which octreotide was used have been
published with variable dosing regimens, length of treatment,
and outcomes and that octreotide was not used in all neonates
(Table 2) [1, 2, 7–14]. A recent systematic review [3] found
octreotide to be eﬀective in 47% of neonates with neonatal
chylothorax. Many of the papers included, however, did not
describe what constituted a clinical improvement or the
timescale over which any changes occurred. In our cohort,
there was no signiﬁcant improvement in the pleural ﬂuid
output in the three neonates treated with octreotide. None of
these neonates reached the dose of 10micrograms/kg/hr
which some studies have used. Multiple side eﬀects have
been reported in up to 14% neonates treated with octreotide
including hyperglycaemia, necrotising enterocolitis, transient
mild cholestasis, transient hypothyroidism, pulmonary
hypertension, and severe hypotension [3]. In our cohort, one
neonate developed transient hypothyroidism.
*e literature review (Table 2) demonstrated only a
minority of neonates required either pleurodesis or thoracic
duct ligation. *is is consistent with the ﬁndings of our
cohort. A review of a case series of neonatal “surgical”
chylothoraces mainly following congenital diaphragmatic
hernia repair also demonstrated conservative management
was successful in the majority [15]. It would be important to
develop evidence-based guidelines as to when such in-
terventions should be used.
4. Conclusions
Our results highlight neonatal chylothorax is an uncommon
condition, but is associated with high healthcare utilisation.
Neonates require stabilisation with ventilation, pleural
drainage, and ﬂuid replacement. MCT feeds can reduce and
stabilise pleural ﬂuid output. It is important to optimise the
dose of octreotide and monitor for side eﬀects. Multicentre
trials are required to identify the optimum evidenced-based
management for neonatal chylothorax. Although neonatal
chylothorax is an uncommon condition, we believe that
Table 2: Case series of neonatal chylothorax.
Author and
year
Number
of
neonates
Ventilation
(days)
Number
given MCT
feeds
Number treated
with octreotide and
dose
Octreotide
duration
(days)
Octreotide eﬃcacy
Pleurodesis or
thoracic duct
ligation
Altuncu et al.
(2007) [5] 3 N/R n� 3
n� 1 (1–10mcg/kg/
hr) 28 No response n� 1
Matsukuma
et al. (2009)
[6]
2 N/R n� 2 n� 2 (0.5–10mcg/kg/hr) 16–20 No response n� 2
Bellini et al.
(2012) [7] 30 30 n� 28
n� 6 (1–10mcg/kg/
hr) 8–38
Decreased chylous
production, but not
quantiﬁed
n� 1
Horvers et al.
(2012) [8] 7 16 n� 7
n� 7 (2–12mcg/kg/
hr)
Median 22
(11–46)
Possible response in two
neonates n� 0
Shah and
Sinn (2012)
[9]
6 30 n� 6 n� 6 (0.5–10mcg/kg/hr)
Median 20
(4–41)
Resolution in ﬁve
neonates n� 0
Downie et al.
(2013) [1] 10 8 n� 7
n� 3 (3.5–10mcg/
kg/hr) N/R
Response in two
neonates: not quantiﬁed n� 0
Landis et al.
(2013) [10] 11 11 N/R
n� 6 (1–13mcg/kg/
hr) N/R No response n� 0
Bialkowski
et al. (2015)
[2]
28 23 n� 25 n� 7 (3–10mcg/kg/hr)
Median 21
(10–45) No response n� 0
Hua et al.
(2016) [11] 4 1 N/R n� 3 (N/A) 14 No response n� 4
Yin et al.
(2017) [12] 14 13 n� 12
n� 3 (1–6mcg/kg/
hr) Median 6
Average drain output
signiﬁcantly lower: three
days after treatment.
Median 62ml versus
133ml (p � 0.002)
n� 0
Shillitoe et al.
(2018) [13] 21 N/R n� 2
n� 1 (maximum
dose 10mcg/kg/hr) N/R
On the maximum dose
there was a 50%
reduction in ﬁve days
n� 0
Zaki et al.
(2018) [14] 9 N/R n� 9
n� 9 (1–10mcg/kg/
hr) 5–66
Resolution in three
neonates: not quantiﬁed n� 0
N/R: not reported.
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multicentre trials would be feasible as shown by the rand-
omised trial of respiratory support in neonates with con-
genital diaphragmatic hernia [16].
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